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Role of temperature in myocardial ischemic injury and 
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Organ temperature and ischemia/reperfusion injury (IRI) are strictly linked. It is well known that deep/profound hypothermia 
can improve cardioplegia induced cardiac preservation. Also mild/moderate hypothermia induces myocardial protection 
against IRI in beating hearts. Here we will focus on some mechanisms of cardioprotection induced by hypothermia. In 
particular, we will analyze the effects of hypothermia on heart metabolism, cytosolic calcium, and oxidation/nitrosation 
processes. The role of inflammation, extracellular matrix processing, genetic, and epigenetic effects in mild hypothermia 
will be also analyzed. Recent advances on miRNA, exosomes, and extracellular vesicles controlled by temperature variation 
will be discussed. Particular emphasis will be given to the procedures of conditioning (pre, per and postconditioning and 
remote conditioning) obtained with thermic and/or ischemic stimuli. In this context hyperthermic processes also play an 
important protective role. From the analyzed studies, it emerges that temperature is an important variable affecting IRI that 
deserves to be strictly controlled and eventually modified to amplify the efficacy of cardioprotective strategies. Nevertheless, 
more in depth studies are necessary to understand the mechanisms of protection induced by thermic therapy alone and in 
association with other cardioprotective interventions. More in depth investigation into the mechanistic signaling that lead to 
temperature triggered protection could individuate crucial targeting molecules, representing strategic knowledge to promote 
a better therapeutic efficacy and a lower cardiovascular risk in the setting of myocardial ischemia/reperfusion.
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1. Introduction 
Animal species that maintain a body temperature higher 
than their environment are commonly called “warm-blooded 
animals.” Among these are birds and mammals, homoeothermic 
species that maintain a stable body temperature by adjusting 
metabolic processes. In homoeothermic species, the internal 
temperature (core temperature) is often higher than the 
immediate environment (Zivadinović et al., 2005; Mitchell et 
al., 2018; Romanovsky 2018). 
Metabolic process that generates heat energy are many, 
among these muscle contraction is one of the most efficient. 
Therefore, during manual work and physical exercise, muscle 
and internal body temperature may be a little higher than the 
typical core temperature of the considered animal (Gleeson 
1998).
Human core temperature is 37 °C (98.6 °F) and can range 
between 36.1 °C (97 °F) and 37.2 °C (99 °F). Body temperature 
of some animals used for experiments is higher than that of 
humans. For example, those of dogs and pigs are between 37.5 
and 39.5 °C while the murine model is similar to human (from 
36.5 to 38 °C) (Ingram and Legge, 1970; Nemoto and Frankel 
1970). During normal life activities, maintaining a constant core 
body temperature is essential for survival of these animals, by 
maintaining optimal organ, tissue, and cellular function.
Usually, with ischemia the temperature of the organ 
decreases, in particular the temperature of those organs and 
parts of the body exposed to room temperature. Furthermore, 
reperfusion exposes organs to rapid variations in temperature. 
In contrast, internal organs, such as the heart, may have little, if 
any, temperature variation during ischemia and reperfusion in 
situ, in the majority of clinical conditions. Yet, in some clinical 
(e.g. during heart surgery) or experimental conditions (e.g. open 
thorax or isolated heart), the heart temperature may randomly 
drop during ischemia. Therefore, the extent of ischemia/
reperfusion injury (IRI) may be influenced by temperature 
variation during such conditions. In some other clinical 
conditions, the temperature is under the control of physicians, 
who try to reduce it during organ ischemia to reduce IRI.
Since temperature plays a pivotal role in determining 
myocardial IRI, many studies considered the role of 
temperature in determining myocardial infarct size. Studies 
also considered the role of temperature in determining the 
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efficacy of conditioning protocols. In this mini-review 
we will analyze the findings of some of these studies in 
homoeothermic animals. Specifically, we provide the current 
state of knowledge regarding therapeutic hypothermia against 
IRI and the mechanisms of hypothermia-induced myocardial 
protection. Moreover, we discuss how it is possible to induce 
cardioprotection by combining conditioning protocols with 
temperature variations.
For an interesting evolutionary and comparative perspective, 
the reader is directed to reviews dealing with hypothermic 
mechanisms of hypoxia tolerance in ectotherms (Tota et al., 
2011) and hibernating mammals (Dave et al., 2012). Indeed, 
myocardial ischemia often leads to devastating damage in 
humans and most other mammals, whereas ectotherms and 
hibernating mammals suffer no ill effects when blood flow 
to an organ is drastically decreased during experimentally 
induced ischemia in euthermia or during torpor. Such models 
might reveal to us some mechanisms that might be exploited in 
humans. 
2. Temperature and ischemia/reperfusion
In mammals, myocardial IRI is a process in which several 
mechanisms are triggered that lead cells to death. During 
ischemia and reperfusion, oxidative stress and calcium 
overload, as well as lowering of ATP levels may reach critical 
levels at which the ability of the cardiac cells to remain viable is 
compromised, and the cells undergo uncontrolled death through 
processes of oncosis and necrosis. Moreover, programmed 
cell death pathways may be initiated including apoptosis, 
necroptosis, and pyroptosis. Each of these cell death types 
contribute to infarct size and may activate different levels of 
the inflammatory response (Davidson et al., 2020). In the last 
few years we have understood that the optimal cardioprotective 
approach may require the combination of synergistic or additive 
multi-target therapies (Davidson et al., 2019).
Temperature is among one of the most important variables to 
control during cardioprotective strategies to reduce cell death 
and inflammatory processes.  Temperature plays a major role 
in determining infarct size in homoeothermic mammals (Chien 
et al., 1994; Hale and Kloner 1997; Schwartz et al., 1997; Guo 
et al., 2012). Indeed, during the ischemic period, infarct size 
is proportional to the temperature of the heart (Miki et al., 
1998). Temperature must be carefully controlled throughout 
the experiment by lamps and heating pads, and must be 
continuously monitored using a stabilized rectal thermometer. 
For example, the heated table and thermal mattress should be 
warmed up to 40-42 °C to maintain the core body temperature 
around 37-38 °C throughout the procedures (Gao et al., 2011; 
Dai et al., 2015; Bøtker et al., 2018).
It seems that even in the absence of ischemia, hearts tolerate 
hypothermia better than hyperthermia (Hale and Kloner 
1997; Tissier et al., 2012). Many studies were conducted 
under hypothermic conditions to assess the cardioprotective 
mechanism of hypothermia before, during, and after ischemia. 
Studies on the protective role of hyperthermia have been also 
carried out (see below). Indeed, hypothermia protects ischemic 
tissue in many organs including heart and brain, increasing 
the rate of a favorable outcome and reducing mortality (Dave 
et al., 2012; Yenari et al., 2008; Savitz et al., 2017). Actually, 
the protective effect of lowering temperature has been known 
since antiquity and hypothermia was put into surgical practice 
early in the 1950’s. In the Classical Greece period Hippocrates 
had already recognized an important role of temperature 
management by inducing cooling during fever (Polderman, 
2004). More recently, Bigelow et al., (1950) applied therapeutic 
hypothermia during cardiac surgery as a form of therapeutic 
myocardial protection. Over the years, the effects of change 
in temperature have been the object of numerous studies and 
represent a critical avenue for development of new therapies. 
Even the first successful open heart operations were performed 
under hypothermic conditions (Lewis and Taufic, 1953). After 
the early applications of hypothermia for brain protection 
during aortic arch repair, this technique has been exploited 
worldwide in aortic surgery (Griepp et al., 1975).
In the cardiology field, besides infarct size reduction, 
mild hypothermia also results in prevention of no-reflow or 
microvascular obstruction, preservation of post-ischemic 
contractile function, and ultimately improvement in cardiac 
remodeling in several animal studies (Tissier, et al., 2012). 
However, previous large clinical studies applying hypothermia 
in patients with ST-segment elevation myocardial infarction 
(STEMI) were disappointing (Grines, 2004). This discrepancy 
between animals and humans could be due to many factors, 
including technical problems that have not made it possible to 
significantly reduce normothermic ischemic times in humans. 
Indeed, more recent trials in which rapid cooling was achieved 
seems more promising in terms of infarct size reduction and/
or limiting the severity of post-ischemic heart failure (Götberg 
et al., 2010; Erlinge et al., 2013, 2014, 2015; Noc et al., 2017) 
(Table 1). Much larger studies are needed to verify these results 
in light of the fact that lowering the temperature below 30 
°C is dangerous and can jeopardize life. Nevertheless, these 
promising trials are a stimulus to better understand the effects 
of temperature in myocardial protection to more safely exploit 
these procedures.
3. Mechanisms of mild/moderate hypothermia-induced 
myocardial protection 
Hypothermia can be classified based on the depth of cooling. 
Therefore, we can have mild hypothermia (32-35 °C), moderate 
hypothermia (28-32 °C), deep hypothermia (28 to 17 °C), and 
profound (<17 °C) hypothermia. Mild/moderate hypothermia 
may be cardioprotective and can reduce infarct size in several 
animal species (e.g. dogs, pigs, rabbits, sheep, and rats) (Tissier, 
et al., 2012). Deep/profound hypothermia has been widely 
used to improve the outcome in many clinical conditions, 
including cardiac arrest, transplantation, hemorrhagic shock, 
and myocardial ischemia. 
The mechanisms underlying hypothermia-induced protection 
of the brain and heart have been studied since the early 1950s 
(Thorn et al., 1957; Kübler, 1967). They have been analyzed 
in recent reviews (e.g. Hale and Kloner, 2011; Tissier et al., 
2012). Therefore, herein we analyze some among the most 
common and recently described mechanisms. Indeed, mild/
moderate hypothermia does not act only via energy saving, it 
acts also through intracellular signaling pathways, intercellular 
communication and other mechanisms (Fig.1). 
3.1 Effects of hypothermia on heart metabolism
Hypothermia protects ischemic myocardium by reducing the 
accumulation of dangerous metabolites and ATP usage. In 
addition, hypothermia also downregulates ATP production by 
mitochondria. Therefore, energy supply/demand ratio alterations 
may occur under hypothermic conditions. 
Mild/moderate hypothermia (below 31 °C) has been reported 
to reduce myocardial injury caused by simulated ischemia/
reperfusion (I/R) protocols by activating cardiac signaling 
pathways for survival. Under hypothermic conditions, energy 
metabolism, mitochondrial calcium homeostasis, and membrane 
integrity are saved and can play a key role in cardiac resistance 
to hypoxia (Huang et al., 2015). 
It is said that for every 1 °C by which the body is cooled, 
cellular metabolism is slowed down by approximately 7% 
(Erecinska and Thoresen, 2003). Studies suggested that a 
temperature threshold exists and a marked decrease in energy 
supply/demand occurs around a certain temperature: in a study 
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conducted in isolated rabbit hearts, it has been suggested that 
the threshold is around 30 °C and that the threshold can be 
modified by providing glucose as a substrate in a cardioplegic 
solution. In this study myocardial ATP concentration was lower 
in 34 °C ischemic hearts than those kept at lower temperature 
and a close relationship between myocardial ATP concentration 
and functional recovery was described. Functional recovery was 
improved by glucose in the group kept at 34 °C (Ning et al., 
1998a).
A few studies analyzed whether left ventricular hypertrophy 
(LVH) may affect myocardial protection by hypothermia or 
cardioplegic solutions and the possible role of metabolism. For 
instance, it has been reported that a 2-h mild hypothermia cannot 
improve long-term survival for hypertensive animals with LVH, 
despite the reduction in circulating levels of damage markers 
(cardiac troponin T and N-BNP) observed after treatment 
with hypothermia (Wang et al., 2016). Yet, cardioplegia 
also adequately protects the hypertrophic myocardium if the 
regional myocardial temperature does not rise above 15 °C 
during cardiac arrest (deep hypothermia). However, hearts with 
a higher LVH displayed reduced myocardial ATP content at the 
end of the period of ischemia (Scheld et al., 1985).
3.2. Role of cytosolic calcium on hypothermia protection
Cytosolic calcium plays a major role in IRI, but magnitude 
and time course of I/R-induced calcium overload remain 
elusive. As recently reviewed, deep hypothermia alleviates 
virtually all known deleterious features of ischemia, including 
calcium overload (Hale and Kloner, 2011; Tissier et al., 2012). 
The mechanisms of mild hypothermia in beating hearts have 
been less studied. An earlier study suggested that the anti-
ischemic and negative inotropic effects of hypothermia are 
somehow similar to those induced by calcium antagonists 
rendering redundant the use of these drugs under conditions of 
hypothermia (Hearse et al., 1984).
Differences exist between hypothermic ischemia and 
cardioplegic arrest in terms of calcium handling. Taking 
advantage of temperature dependent variations in the 
dissociation constant of fluorescent probes used to measure 
cytosolic Ca2+ concentration, it has been suggested that cytosolic 
Ca2+ concentration accumulation occurs during hypothermic 
ischemia with cardioplegic arrest, as well as during unprotected 
ischemia, without further net Ca2+ influx upon reperfusion 
only under hypothermic conditions. Thus, reducing calcium 
overload in reperfusion. Moreover, mild hypothermia inhibited 
calcium-induced mitochondrial permeability transition pore 
(mPTP) opening in ischemic rabbit hearts (Tissier et al., 2009). 
These findings may have important implications for timing of 
protective strategies during myocardial ischemia/reperfusion 
(Stamm et al., 2003). Intriguingly, cold cardioplegia not only 
blunts mitochondrial calcium overload during ischemia/
reperfusion, but also the generation of reactive oxygen species 
(ROS) at reperfusion (see below) (Riess et al., 2004; Gambert et 
al., 2004). This ROS reduction may be due to a limitation of the 
so-called ROS-induced ROS release phenomenon, supported by 
calcium overload and mPTP opening during reperfusion (Penna 
et al., 2013; Tullio et al., 2013).
3.3 Temperature and oxidation/nitrosation
Low temperature alters mitochondrial membrane composition 
and mitochondrial ROS production in muscle cells (Guderley 
2004). Low temperatures sustained for 14 days affects free 
radical lipid oxidation and antioxidant levels in the tissues 
of different organs (liver, kidneys, lungs, and heart). It has 
been suggested that the activation of antioxidant enzymes as 
a consequence of the increase in the rate of lipid peroxidation 
depends on low temperature exposure time (Nikolaev et al., 
2018). 
Profound (4 °C) hypothermia during the ischemic period 
results in a reduction of ROS generation and in an improvement 
of functional recovery in isolated reperfused (30 min, at 37 °C) 
rat heart (Gambert et al., 2004). A reduction of ROS generation 
was observed also during short-term 17 °C ischemia (Riess et 
al., 2004). In a pioneering work, Magni and colleagues reported 
that after a period of 1-h deep hypothermia, complete functional 
recovery was obtained upon return to normothermia; however, 
3-hours of hypothermia induced irreversible deterioration of 
the electrical and mechanical heart function, with an increase 
in lipid peroxidation on rewarming, resulting in a decrease in 
reduced glutathione levels. Perfusion with a solution containing 
chelating iron avoided both the increase in lipid peroxidation 
and the deterioration in heart function (Magni et al., 1994). 
These data suggest that iron-dependent lipid peroxidation is 
responsible for time-dependent cold-induced injury.
Figure 1. Main mechanisms of hypothermia induced cardioprotection. It is likely that these mechanisms are interconnected.
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Mild hypothermia (32 °C) attenuated ROS generation 
at reoxygenation in a murine cardiomyocyte model. In this 
model hypothermia was applied 10-min before reoxygenation 
and maintained for 1-h, after 90-min simulated ischemia 
(Shao et al., 2010). Moreover, this mild hypothermia-induced 
cardioprotection was abolished by inhibitors of Akt and nitric 
oxide (NO) synthase (NOS) but not by a cyclic GMP (cGMP) 
inhibitor (Shao et al., 2010). Similar results were demonstrated 
in an isolated rat heart. In particular, hypothermia increased NO 
synthesis and maintained mitochondrial membrane potential, 
while enhancing phosphorylation of both Akt and heat shock 
protein-27 (HSP-27) during ischemia. The lack of a role for 
cGMP, together with an enhanced production of NO and a 
reduced amount of ROS suggest a prevalent role of nitrosylation 
processes rather than the classical cGMP/PKG signaling 
pathway in the hypothermia induced protection in this model. 
The protective effects of hypothermia were abolished with 
either inhibition of NO generation with L-arginine analogues or 
blockade of phosphoinositide 3-kinase (PI3K) with wortmannin 
(Mochizuki et al., 2012). These studies suggest a pivotal role 
for oxidative/nitrosative signaling in hypothermia-induced 
cardioprotection.
Also high temperature affects mitochondrial respiration 
and ROS production (Christen et al., 2018). Indeed, in 
mammals, heart mitochondria are extremely sensitive to 
increases in temperature (Lemieux et al., 2017). Nevertheless, 
the relationship between mitochondria, oxidative status, and 
temperature has yet to be fully characterized.
3.4 Inflammatory signaling modulation by hypothermia
The redox and inf lammatory  responses  are  s t r ic t ly 
interconnected in several cardiovascular diseases and following 
IRI (Hernandez-Resendiz et al., 2018; Ong et al., 2018). 
Therefore, targeting the inflammatory response is among the 
most promising protective mechanism of hypothermia (Diestel 
et al., 2008; Yang et al., 2009, 2010). Studies have shown that 
hypothermia protects against tumor necrosis factor-alpha-
induced endothelial inflammatory dysfunction and apoptosis 
through a MAPK phosphatase-1-dependent mechanism 
(Yang et al., 2010) and via inhibition of JNK1/2 and ERK 1/2 
phosphorylation (Yang et al., 2009). Moreover, hypothermia 
reversed I/R-induced modulation and expression of several 
inflammatory factors (such as cleaved caspase-3, PARP, Fas/
caspase-8, Bax, and Bcl-2) and reduced NF-κB-dependent pro-
inflammatory gene expression (Diestel et al., 2008; Yang et al., 
2009). All in all, these studies support a beneficial role for mild 
hypothermia against the inflammatory response.
3.5 Role of extracellular matrix processing in hypothermia 
protection
Ischemia/reperfusion damage activates early extracellular 
matrix processing and, indeed, an increase in cleavage 
products of matrix plays a role in determining damages after 
ischemia/reperfusion leading to heart failure. In a recent study 
this cleavage was observed in normo-thermic ischemia only 
(Lauten et al., 2014). IRI not only activated extracellular matrix 
processing, but also enhanced expression of Collagen 18A1/
Endostatin in the heart with dissimilar effects of temperature. 
These data suggest that processing of myocardial extracellular 
matrix starts early after I/R and depends on temperature levels, 
which may influence the progression to heart failure (Lauten et 
al., 2009).
3.6 Genetic and epigenetic effects of mild hypothermia
Besides modulating both myocardial energy requirement and 
production, myocardial protection induced by hypothermia 
may be accompanied by an up-regulation of the expression 
of genes regulating heat-shock-proteins and nuclear-encoded 
mitochondrial proteins, such as the beta subunit of F1-ATPase 
(beta F1-ATPase) and the adenine nucleotide translocator 
isoform 1 (ANT1). Maintenance of gene expression for 
mitochondrial proteins suggests that signaling for mitochondrial 
biogenesis or re-synthesis is preserved even after ischemic 
challenges. Ning et al. (1998b, c) showed that mRNA 
expression for ANT1 and beta F1-ATPase was maintained in a 
pattern consistent with the temperature threshold phenomenon (a 
marked decrease in energy demand occurs at 30 °C, suggesting 
that this temperature is a sort of threshold), whereas HSP70-1 
expression was not influenced by temperature during ischemia 
(Ning et al., 1998b, c; Xu et al., 1998). 
Epigenetics can be defined as meiotic and mitotic changes in 
gene expression that do not involve a change in DNA sequence 
igure 2. Schematic representation of the various protocols of ischemic or thermic conditioning. White boxes represent time of normal 
perfusion or reperfusion; black boxes are periods of index ischemia; dark gray boxes represent periods of conditioning with brief ischemia or 
thermic procedures. The number and duration of conditioning cycles used can vary with different experiments and clinical conditions.
PreCon: preconditioning; PostCon: postconditioning; Per-Con: perconditioning.
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and can be heritable. Two major areas of epigenetics, DNA 
methylation and histone modifications, may have profound 
effects on controlling gene expression. A few studies have 
analyzed the effect of temperature on epigenetics. Among these, 
studies in fishes, flies, mosquitos, and plants have reported 
temperature-induced epigenetic inheritance (Bonasio 2015; Xu 
et al., 2019). A study on male mice exposed to cold induced 
alterations in DNA methylation in their sperm associated with 
alterations in gene expression that resulted in metabolic changes 
in offspring (Sun et al., 2018).  To the best of our knowledge, 
the only study that examined epigenetics during therapeutic 
hypothermia in cardiac pathophysiology is the study by Liu 
et al. (2019). In this study cardiac proteomes revealed that 
cold-inducible RNA binding protein (CIRBP) was decreased 
in rats exposed to chronic hypoxia during cardiopulmonary 
bypass. Methylation analysis of neonatal rat cardiomyocytes 
and myocardium samples from patients with chronic hypoxia 
showed that hypoxia induced hypermethylation of the Cirbp 
promoter region, resulting in its downregulation and failure to 
respond to cold-stress. While Cirbp-transgenic rats displayed 
enhanced hypothermic cardioprotection, cirbp-knockout rats 
displayed an attenuated response. Analysis of epigenetic 
modification of Cirbp might help to personalize the use of 
therapeutic hypothermia in cardiac pathophysiology.
3.6.1 miRNA and Hypothermia
In a variety of conditions, including organ injury and 
temperature variations, organs and cells release tissue-specific 
circulating micro ribonucleic acids (miRNAs) into the blood. 
miRNAs were first described three decades ago as small non-
protein coding RNAs (Lee et al., 1993). They bind to messenger 
RNA to regulate messenger RNA expression. By modulating 
cellular proliferation, differentiation, and programmed cell 
death, microRNAs may have a pivotal role in many clinical 
conditions, including myocardial infarct, tumorigenesis, 
and metastases. Circulating miRNAs, released from injured 
myocardium could have some prognostic value in patients who 
have suffered acute coronary syndromes (Widera et al., 2011).
In a recent article Squiers et al. (2015) wondered whether 
miRNA modulation might affect an old strategy such as 
hypothermic organ protection.  In an ischemic porcine 
cardiogenic shock model, the release pattern and plasma level 
of cardiac-specific miR-208b and liver-specific miR-122 during 
therapeutic mild hypothermia (33 °C) have been examined. 
The results of this study indicated that therapeutic hypothermia 
blunted the increase in miR-122 only. Data from this study 
confirmed that liver-specific miR-122 is released into the 
circulation in the setting of cardiogenic shock and suggested 
that therapeutic hypothermia reduces the plasma levels of miR-
122. Yet, treatment with hypothermia after cardiac reperfusion 
did not modify the plasma levels of miR-208b (Andersson et 
al., 2012).
Recently, Wang et al. (2015) reported that inhibiting miR-
29c with antagomiR-29c (an antagonist of miR-29c) protected 
the rat brain in a model of prolonged hypothermic circulatory 
arrest. Notably, miRNA miR-29c is a regulator of peroxisome 
proliferator–activated receptor γ coactivator 1α (PGC-1α), 
which is a modulator of mitochondrial biogenesis and regulator 
of mitochondrial metabolism. Therefore, this study confirms 
and improves our knowledge on the effects of hypothermia in 
modulating metabolism. In a study aimed at testing small non-
coding RNAs as references in quantitative RT-PCR expression 
analyses, it has been found that RNU6B is a useful marker 
for differentiating hypothermia deaths from chronic ischemic 
heart disease deaths (Kaija et al., 2020). Stammet et al. (2012) 
measured serum miRNA levels 48-h after cardiac arrest in 
patients that had undergone therapeutic hypothermia. These 
authors found that miR-122 and miR-21 levels were particularly 
high in patients who had poor neurologic outcomes. However, 
neuron-specific enolase (NSE) was a more accurate predictor of 
neurologic damage than the miRNAs. Yet, these miRNAs did 
not correlate with markers of myocardial injury or inflammation 
in these patients.  These and other studies (Gilje et al., 2014; 
Devaux et al., 2015; Lin et al., 2015) pave the way for future 
studies to confirm the role of miRNAs as new biomarkers of 
organ damage or protection, and as therapeutic targets during 
hypothermia and cardiac arrest.
3.7 Effects of temperature on exosomes and extracellular 
vesicles 
Exosomes and extracellular vesicles (EVs) are miRNAs 
carriers. They carry many other factors and have been 
implicated in intercellular communication, including 
transmitting protection or malignancy. It has been demonstrated 
that adult cardiomyocytes release heat shock protein (HSP-
60) both as free protein and carried in exosomes. Whether 
hypothermia modifies the release of cardiac exosomes and 
extracellular vesicles is unknown. To the best of our knowledge, 
while a number of studies considered the role of exosomes 
and EVs either during fever or hyperthermia (Tytell, 2005), 
demonstrating that, for example, fever changes exosome 
permeability (Malik et al., 2013), only a few studies considered 
exosomes as a biomarker of hypothermia injury/protection. It 
seems that the turnover of exosomes in the peripheral blood 
is sufficiently rapid to be clinically useful to evaluate the 
therapeutic response during hypothermia (Goetzl et al., 2017). 
This is a fertile field to be studied.
4. Deep/profound hypothermia to improve cardioplegia in 
mature and immature hearts
Cardioplegia is protective in the ischemic adult heart both 
under normothermic and hypothermic conditions regardless of 
whether it is administered once or multiple times. The additive 
protective effect of hypothermia and chemical cardioplegia 
in adult dogs has been previously reported (Rosenfeldt et al., 
1980). Nowadays, the standard technique of heart preservation 
is cardiac arrest followed by static-cold-storage (SCS) in a 
crystalloid preservation solution. These procedures have been 
reviewed several times. Here we mention only the key steps.
Several strategies have been considered to improve 
heart storage. These include, supplementation of SCS with 
hyperpolarizing and/or anti-ischemic agents, novel formulations 
of heart preservation solutions, donor heart perfusion with 
perfusion systems, perfusion (persufflation) of donor heart with 
gaseous O2, pre- and post-conditioning of cardiac graft (see 
below), and/or donor heart preservation at sub-zero temperature 
(for review see Minasian et al., 2015).
Several studies evaluated the influence of temperature to 
preserve donor heart and to minimize cardiac dysfunction 
caused by IRI, which would inevitably occur during the ex 
vivo transport period without protection. Although myocardial 
O2 consumption decreases drastically during SCS of the donor 
heart at +4 °C, several attempts to further minimize cardiac 
energy demand and to better preserve heart function by 
myocardial cooling to different or sub-zero temperatures have 
been attempted.  For instance, Natsuaki et al. (1983) evaluated 
the optimal myocardial temperature during 4-h ischemia 
induced by blood potassium cardioplegia. They compared 
moderate hypothermia and deep hypothermia and two perfusates 
(with blood or without blood). Indeed, in blood potassium 
cardioplegia (GIK cardioplegia) at moderate hypothermia, 
dangerous acid metabolites were scarcely produced and cardiac 
function was recovered. Specifically, the authors observed 
a decrease in pH to 6.88 of coronary sinus blood during 
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unprotected reperfusion and to pH 7.22 after GIK cardioplegia, 
suggesting better preservation of high energy phosphate 
(Natsuaki et al., 1983). These authors concluded that blood 
GIK cardioplegia at moderate hypothermia allows the heart to 
tolerate 4-h ischemia without an excessively elevated coronary 
perfusion pressure during cardioplegic infusion. Subsequently 
Sakaguchi et al. (1996) evaluated the ability of the hypothermic 
simple immersion technique to individuate the temperature 
providing the best protection against prolonged ischemia. These 
authors concluded that hearts subjected to subzero temperatures 
resulted in significantly better cardiac output, aortic flow, and 
aortic systolic pressure than the control group. Myocardial ATP, 
ADP, and total adenine nucleotides at end-storage were better 
preserved. The authors proposed that storage in the intracellular 
type solution at subzero nonfreezing (-1 °C) temperatures as 
compared with 4 °C appears to prolong myocardial preservation 
improving the enhancement of post-ischemic functional 
recovery, preservation of myocardial adenine nucleotides 
during ischemia, and prevention of myocardial edema at 
reperfusion. To prevent irreversible cell injury induced by 
freezing, cardioplegic solutions have been enriched with anti-
freeze proteins (AFPs) endowed with cryoprotective properties. 
For example, rat hearts stored in the University of Wisconsin 
(UW) solution containing AFP-I or AFP-III at −1.3 °C for 21-h 
showed better left ventricle function and a lower occurrence 
of apoptosis after heterotopic transplantation when compared 
with controls (Amir et al., 2004). A promising method of sub-
zero heart storage has been proposed: in this method, rat hearts 
were placed in a UW-solution and submerged into a variable 
magnetic field at minus 3 °C. The hearts were stored for 24-h 
and then subjected to 120-min reperfusion. The sub-zero storage 
resulted in decreased tissue edema and an amelioration of post-
ischemic left ventricle function and myocardial ATP level 
(Kato et al., 2012). However, Bernard et al. (1998) using P-31 
magnetic resonance spectroscopy and biochemical analyses 
compared the influence of two different cold temperatures 
(below 10 °C) for cardiac ischemia by measuring a large variety 
of metabolic and hemodynamic parameters during ischemia and 
reperfusion. They concluded that storage at +7.5 °C provides 
better protection than storage at +4 °C. 
The picture is further complicated if immature hearts (heart 
of a few days old animal) are considered. Indeed, detrimental 
TH: therapeutic hypothermia; AMI: acute myocardial infarction; MACE: major adverse cardiac events; PCI: percutaneous coronary intervention; 
IS: infarct size; SPECT: single photon emission computed tomography; MRI: magnetic resonance imaging; MaR: myocardium at risk; MI: 
myocardial infarction; STEMI: ST elevation myocardial infarction.
Table 1: Summary of clinical studies using variable strategies of therapeutic hypothermia.
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or beneficial effects of hypothermic cardioplegia in the 
immature hearts have been reported. For instance, studies 
have demonstrated that single-dose cardioplegia is protective 
under different hypothermic conditions in the immature 
heart. However, multidose cardioplegia affords even greater 
protection at 20 °C but was deleterious at 10 °C. These studies 
concluded that, in contrast to the situation in the adult, more 
"extreme" hypothermia may be damaging in the immature 
heart when combined with multidose cardioplegia (Kempsford 
and Hearse, 1990). The same group of authors confirmed that 
in the neonatal rabbit heart the cardioprotective properties of 
multidose cardioplegia relative to single-dose cardioplegia are 
progressively lost as the heart temperature decreases (Murashita 
and Hearse, 1991). Therefore, the ideal temperature for heart 
storage is still a matter of debate, and may be influenced by 
several factors, including the age of the heart donor. The reader 
is redirected to specific reviews on this topic for a more in depth 
discussion (e.g. Minasian et al., 2015; Macdonald et al., 2016).
5. Possible adverse effects of hypothermia
Recently, two systematic reviews on adverse effects following 
therapeutic hypothermia have been published (Karcioglu et al., 
2018; Lindsay et al., 2018). From these two reviews one can 
understand that several adverse effects and/or complications can 
occur during hypothermia in patients resuscitated from out-of-
hospital cardiac arrest. The lower the temperature is, the higher 
the risk of complications (temperature below 30 °C jeopardize 
life). Side effects include important cardiac adverse effects such 
as ventricular dysrhythmias and coronary vasoconstriction, 
as well as coagulopathies. Regarding this latter side effect, it 
has been suggested that hypothermia progressively impairs 
platelet aggregability and coagulation cascade, thus impairing 
clot formation and hemostasis (De Robertis et al., 2015). Mild 
hypothermia (33-37 °C) slightly reduces platelet adhesion 
only, while temperatures below 33 °C reduced both platelet 
function and coagulation cascade efficiency, resulting in 
hemostasis defects (Wolberg et al., 2004). Contradictory results 
have been reported about platelet aggregatory response to 
classical aggregatory stimuli in the presence of mild/moderate 
hypothermia (Scharbert et al., 2006, 2010). Therefore, whether 
platelet dysfunction is a central mechanism of hemostasis 
impairment during mild/moderate hypothermic strategies 
remains to be ascertained by further studies.
As said, mild/moderate therapeutic hypothermia has been 
extensively used to protect the heart and the brain in several 
clinical settings. In many of these studies the risk of severe 
adverse effects associated with therapeutic hypothermia seems 
to be very low (Polderman, 2009; Nielsen et al., 2011; Delhaye 
et al., 2012). It is likely that a controlled process of cooling in 
hospital does not induce the side effects observed in accidental 
hypothermia or in pre-hospital therapeutic hypothermia. 
Indeed, the aforementioned systematic reviews conclude that 
therapeutic hypothermia does not cause unfavorable effects 
leading to significant alterations in the outcomes of the patients 
following resuscitation (Karcioglu et al., 2018; Lindsay et al., 
2018). Also, from the clinical studies reported in Table 1, it 
can be deduced that the safety of these strategies is acceptable. 
However, the possibility of major side effects should always be 
considered during therapeutic hypothermia.  
6. Temperature and conditioning
Increased myocardial tolerance to IRI after brief (a few 
minutes) episodes of coronary ischemia–reperfusion is referred 
to as ischemic preconditioning (PreCon) (Murry et al., 1986). 
Ischemic PreCon triggers the most effective endogenous 
cardioprotective mechanisms developed thus far (Penna et 
al., 2015). Distinct windows of opportunity for clinical use 
of conditioning procedures have been elucidated: whilst the 
conditioning stimulus is applied before the index ischemia in 
PreCon, it is applied immediately after the index ischemia in 
postconditioning (PostCon). PreCon and PostCon ischemic 
stimuli (a few minutes of intermittent ischemia) can be applied 
in a different/remote organ, which are referred to remote PreCon 
and remote PostCon, respectively. In the case of ischemic 
remote conditioning, the procedure of intermittent ischemia 
can also be performed during the index event, in the so-called 
remote per-conditioning (Per-Con) (Penna et al., 2015) (Fig 2).
As described above, traditionally, hypothermia is used 
prior to surgery as a protective measure under conditions of 
prolonged organ ischemia, such as organ transplantation and 
open-heart surgery. The therapeutic efficacy of hypothermia in 
acute cases of ongoing ischemia such as myocardial infarction, 
stroke, and cardiac arrest has been considered. Here we 
consider and discuss the possibility of inducing protection in the 
three distinct windows (PreCon, Per-Con, and PostCon) with 
temperature variations alone or in association with ischemic 
conditioning (Fig 2), especially in acute settings.
6.1 Preconditioning procedures
PreCon with ischemia and/or temperature variations can be 
studied in animal experiments in the setting of myocardial 
infarction. For successful translation of myocardial PreCon 
to clinical use at least two conditions are necessary: 1) the 
predictability of ischemia onset and 2) direct access to the 
heart; both of these conditions are fulfilled during programmed 
revascularization interventions and during heart transplantation. 
We review first the studies considering temperature variations 
and ischemic PreCon for heart storage, then the studies analyzing 
these two procedures alone or in combination in the setting of 
acute ischemia/reperfusion in the beating heart.
6.1.1 Ischemic PreCon plus hypothermic heart storage 
It seems that when used in association with the standard 
techniques of heart preservation, ischemic PreCon may be of 
value in protecting the heart against IRI. Karck et al. (1996) 
were among the first to demonstrate that ischemic PreCon 
enhances donor heart preservation in the setting of prolonged 
heart storage with hypothermia. They reported an improved 
post-ischemic left ventricle performance recovery after a single 
5-min cycle of normo-thermic I/R just prior to 10-h of heart 
storage at 4 °C. Also Landymore et al. (1998) reported that one 
episode of ischemic PreCon can reduce myocardial stunning 
and can increase tissue ATP levels after heart transplantation. 
Moreover, it has been reported that the protective effect of 
ischemic PreCon on cardiac grafts could be further augmented 
by pharmacological preconditioning with the inhibitor of the 
Na+/H+ exchanger, cariporide (Kevelaitis et al., 2001).
Zhu et al., (2004) demonstrated that ischemic PreCon 
obtained with brief intermittent ischemia of a certain duration 
(between 5- and 15-min) could attenuate the IRI also on 
immature rabbit hearts when St. Thomas crystalloid cardioplegic 
solution is applied during sustained mild hypothermic (32 
ºC) ischemia period. Therefore, it seems that in this delicate 
setting of immature hearts, ischemic PreCon can allow the 
use of less dangerous hypothermic approaches. Despite these 
positive experimental results, to the best of our knowledge the 
combination of donor heart hypothermic storage and ischemic 
PreCon has not been performed in clinical scenarios.
6.1.2 Temperature PreCon and/or ischemic PreCon in the 
beating heart
Halestrap and collaborators reported the possibility of 
preconditioning the heart with intermittent hypothermia 
in a similar fashion to ischemic PreCon (Khaliulin et al., 
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2007, 2010, 2011). They observed that brief episodes of 
moderate hypothermic perfusion (< 32 °C), separated by brief 
periods of normothermic (37 °C) myocardial perfusion, are 
cardioprotective against infarct size induced by normothermic 
infarcting ischemia and 60-min reperfusion (37 °C). This 
procedure is referred to as cold temperature preconditioning 
(cTP).
These authors demonstrated that cTP could protect hearts 
against IRI better than ischemic PreCon (Khaliulin et al., 2007). 
They showed that cTP is more protective than a single 6-min 
hypothermic perfusion at conferring cardioprotection. Either 
ischemic PreCon or cTP protocols augmented myocardial levels 
of high energy phosphates. Moreover, cTP reduced necrotic 
injury, improved hemodynamic recovery, and decreased 
arrhythmias during reperfusion. Assessment of myocardial 
NAD+ levels and calcium-induced swelling of mitochondria 
isolated after 3 min reperfusion suggested greater inhibition 
of the mPTP during reperfusion by cTP than ischemic 
PreCon; these effects were associated with decreased protein 
carbonylation (marker of oxidative stress). Therefore, the 
protective effects of cTP may be due to inhibition of mPTP 
formation and redox stress. Indeed, cTP enhanced protein 
kinase C-epsilon (PKCƐ) translocation to the particulate 
fraction and pre-treatment with a PKC inhibitor blocked the 
cardioprotective effect of cTP. The phosphorylation of AMP-
activated protein kinase (AMPK) was also upregulated by 
cTP. Thus, cardioprotection by cTP was partially blocked by 
an AMPK inhibitor. The presence of N-(2-mercaptopropionyl) 
glycine during cTP also abrogated the protection, indicating 
an involvement of ROS in the cardioprotective signaling 
mechanism. Therefore, the protective signaling pathway may 
initially involve ROS signaling with subsequent activation 
of PKCε and AMPK, thus resulting in reduced opening of 
the mPTP. Subsequently Halestrap and colleagues, using 
a pharmacological approach, confirmed that the signal 
transduction pathway of cTP involves PKC activation that 
follows protein kinase A (PKA) activation (Khaliulin et al., 
2010). It has been also proposed that hypothermia applied 
before ischemia saves ATP stores during subsequent ischemia/
reperfusion and preserves myocardial function at reperfusion. 
In this study enhanced signaling for mitochondrial biogenesis 
is also present during a 12-fold increase in HSP70-1 mRNA 
induced by hypothermia, as shown by beta-F1-ATPase and 
ANT1 mRNA levels (Ning et al., 1998a).
Halestrap’s group studied also the optimal temperature for 
TP and whether cTP further augments protection provided by 
hypothermic ischemia with or without cardioplegia. cTP at 
26 °C resulted in the strongest cardioprotection, augmented 
the concentration of cAMP, and the activity of PKA. On the 
contrary, cTP at 7 °C aggravated IRI, and had no effect on either 
cAMP concentration or PKA activity. The authors concluded 
that cTP at 26 °C bestows additional protection to hypothermia 
and cardioplegia that could be used during heart surgery and 
transplantation (Khaliulin et al., 2011).
Studies examined whether combining ischemic PreCon and 
regional hypothermia during coronary artery occlusion could 
provide better cardiac protection than either intervention alone. 
These studies obtained conflicting results. A study by Hale and 
Kloner (1999) showed that the combination therapy significantly 
improved regional myocardial blood flow in the previously 
ischemic region to a greater extent than either treatment alone 
(Hale and Kloner, 1999). In a study by van den Doel et al. (1998) 
moderate hypothermia (30-31 °C) modestly reduced infarct 
size, but this limitation was attributed to a reduction in the at 
risk area. However, moderate hypothermia markedly enhanced 
the cardioprotection induced by ischemic PreCon in the beating 
rat heart. Therefore, the authors concluded that the combination 
could limit the irreversible damage produced by longer periods 
of coronary artery occlusions (van den Doel et al., 1998). In a 
study by Juggi et al. (1997), ischemic PreCon when combined 
with hypothermia attained no additional protection. In another 
study moderate/deep hypothermia (23 °C) did not affect the 
protective effects of ischemic PreCon, but ischemic PreCon 
was no longer protective in profound hypothermia (6-8 °C) 
(Takeshima et al., 1999).
Miki et al. (1998) tested whether cooling established 
before or during ischemia can limit infarction and be additive 
to protection observed with ischemic PreCon. In this study 
rewarming started upon reperfusion in all protocols. The authors 
demonstrated strong cardioprotective effects of moderate 
cooling (32 °C) started before ischemia and a less potent 
protection when cooling was instituted 10- or 20-min after 
the onset of ischemia. Nevertheless, only this latter protection 
(hypothermic Per-Con; see below) could augment the protective 
effect induced by ischemic PreCon. The authors suggest that 
the cooling and ischemic PreCon use different mechanisms. 
If confirmed this is an important observation as cooling after 
the onset of ischemia can be considered a sort of Per-Con, 
which has the potential to be used in the clinical arena during 
myocardial infarction. Actually, a study suggests that ischemic 
PreCon induces additive protection with mild hypothermic 
myocardial ischemia by improving mitochondrial bioenergetics 
during and after ischemia. In this study a variation in NADH 
and flavin adenine dinucleotide (FAD) levels were considered a 
sign of improved mitochondrial redox balance during and after 
mild hypothermic ischemia and were attributed to mitochondrial 
KATP channel opening (An et al., 2005). Therefore, it seems 
that cooling can be easily induced and is well tolerated by the 
heart. It is not harmful and in some conditions hypothermia can 
protect the heart against infarction especially when it is started 
immediately after the onset of coronary occlusion. Moreover, 
in programmed events hypothermia can be additive with 
protection induced by ischemic PreCon. 
Yet, we should consider that ischemic conditioning during 
simultaneous hypothermia may not be effective because 
hypothermia could not only be protective against ischemia, but 
it could also prevent ischemia from triggering cardioprotective 
pathways. This is supported by studies examining the efficacy 
of ischemic PreCon at different temperatures (Dote et al., 1998; 
Ghadhanfar and Juggi, 2007). Ghadhanfar and Juggi compared 
the efficacy of ischemic PreCon induced in hypothermic (10, 
20 or 30 °C), normothermic (34 or 37 °C), or hyperthermic (40 
degrees C or 42 °C) conditions, in the isolated rat heart model. 
In this study PreCon was induced by two episodes of 5-min 
ischemia at the designated PreCon temperature and 10-min of 
reperfusion, respectively. Subsequently, hearts were subjected to 
global ischemia at 34 °C for 60-min followed by reperfusion for 
30-min at the same temperature, during which the post ischemic 
recovery in contractile and coronary vascular functions was 
assessed. Hyperthermic ischemic PreCon provided optimal 
cardioprotection and increased tolerance to ischemia. 
Hypothermia plus ischemic PreCon was comparatively less 
effective, and normothermia plus ischemic PreCon resulted in 
an intermediate increase in tolerance to ischemia. These data 
support the idea that hypothermia increases the threshold for 
ischemic preconditioning. An idea that was previously suggested 
by other authors (Lu et al., 1997; Dote et al., 1998). The results 
of these studies indicate that the extent of reversibility of 
ischemic damage depends on the preconditioning temperature. 
Therefore, it is suggested that hypothermia (<34 °C) during 
the preconditioning period must be avoided to elicit the best 
protection against infarction by ischemic PreCon, and that the 
ideal ischemic PreCon temperature is higher (between 40 and 
42 °C) than normothermia (37-38 °C). 
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6.1.2.1 Protection by hyperthermia
Actually, hyperthermia was the first stress shown to trigger the 
synthesis of heat stress proteins (HSPs). In particular, a study 
in 1983 (before ischemic preconditioning was introduced) 
reported that whole body hyperthermia (42 °C for 15 min) 
could induce the expression of HSP70 in the heart and other 
tissues (Currie and White, 1983). Subsequently it was reported, 
by the same group, that pre-ischemic hyperthermia could 
improve post-ischemic cardiac functional recovery (Currie 
et al., 1988). Since then several studies have reported that 
the heart can be preconditioned by heat stress (HS). It seems 
that HS-PreCon is able to induce only delayed myocardial 
protection against IRI, which is similar to the second window of 
protection induced by ischemic PreCon (Pagliaro et al., 2001). 
HS-PreCon can reduce cellular necrosis, preserve ventricular 
and coronary endothelial functions, and limit arrhythmia 
occurrence (reviewed in Joyeux-Faure et al., 2003). A recent 
study confirmed that a long period of recovery (72-h) between 
HS-Precon and achievement of protection is necessary (Ilievska 
et al., 2018). The main reason for this delayed protection is 
because the mechanisms that underlie HS-PreCon mainly 
involve new synthesis of proteins that require time, such as 
HSPs and antioxidant enzymes induced by heat and by redox 
signaling. Indeed, several studies have shown that HS-PreCon 
induced by whole body hyperthermia (40-42 ° C for 15-20 
min) is associated with induction of HSPs (Yamashita et al., 
1998; Kevelaitis et al., 2001; Xi et al., 2001; Broderick, 2006; 
Vogt et al., 2007), but some studies questioned whether these 
proteins or antioxidant enzymes are the principal end-effector 
of the protection (Abe et al., 2000; Xi et al., 2001). It seems 
that whole body hyperthermia can induce delayed protection 
against various forms of injury in heart, brain, liver, lungs, 
skeletal muscle, and the small intestine, as well as against lethal 
endo-toxemia. An increase of body temperature to 39-42 ° C 
has been also suggested as novel treatment against the increase 
in oxidative stress in obesity-related metabolic syndromes and 
diabetes (Medina-Navarro et al., 2009; Okada et al., 2004). In 
cardiac protection against IRI a role for PKC, MAP kinases, 
ATP-sensitive potassium channels, ROS, and NO in the 
protective signaling cascade has been reported (Yamashita et 
al., 1998; Kevelaitis et al., 2001; Xi et al., 2001; Joyeux-Faure 
et al., 2003; Broderick, 2006; Vogt et al., 2007).
Whole body hyperthermia does not specifically target the 
organ of interest and may have adverse side effects on blood, 
potentially limiting the safety of HS-PreCon (Walker et al., 
1993). Therefore, some studies have analyzed the possibility of 
inducing cardioprotection using a lower temperature for longer 
periods or heating only the heart with some device. Su et al. 
(1999) used a 39 °C pre-conditioning, which triggered thermo-
tolerance and oxidative resistance in H9c2 cardiac myoblasts. 
Unfortunately, this study was conducted only in vitro and 
deserves validation in other models. A more interesting 
approach is that proposed by Motamedi and coworkers, who 
used heating probes that required direct mechanical contact with 
the surface of the heart or a radiant volumetric laser that did not 
require a direct contact for sub-lethal local heating of the heart 
(42 °C for 20 min). Both approaches improved myocardial 
salvage by preconditioning the myocardium against reperfusion 
injury 4 hours after the heating application (Gowda et al., 1998; 
Gong et al., 2008). Unfortunately, to elevate and maintain 
tissue temperature at the desired temperature with these devices 
the chest must be opened. To the best of our knowledge no 
studies have attempted “local heating” with an intravascular 
or transthoracic device, which would be more appealing for 
clinical use.
6.1.3 Per-Conditioning and Postconditioning procedures
Ischemic PostCon is the intriguing phenomenon whereby brief 
stimuli (e.g. a few seconds of intermittent ischemia) are applied 
in one organ immediately after artery reopening to render the 
tissue resistant to reperfusion injury. Per-Con can be attained 
by applying the stimuli (e.g. brief remote ischemia and/or organ 
cooling) during the index ischemia. The paradigms of ischemic 
Per-Con and PostCon may be particularly relevant, as they 
extend the usefulness of conditioning procedures to reduce 
reperfusion injury into the clinical arena.
The application of hypothermia during ischemia may be 
considered a sort of hypothermia Per-Con. The majority of 
authors agree on the effectiveness of cooling during ischemia 
starting as early as possible (hypothermia Per-Con: reducing the 
temperature earlier by 3 °C may reduce infarct size similarly to 
ischemic PreCon); however a debate exists regarding the benefit 
of mild hypothermia applied during reperfusion (hypothermia 
PostCon) to limit IRI (Tissier et al., 2011). The majority of 
studies suggest that hypothermia limits ischemic injury rather 
than reperfusion injury (Hale et al., 1997; 2003; van den Doel 
1998; Tissier et al., 2007, 2009).
As mentioned above, in a study where moderate cooling 
was applied immediately after the onset of acute myocardial 
ischemia (i.e. hypothermic Per-Con) Miki et al. (1998) observed 
an appreciable reduction in infarct size. More recently it has 
been confirmed that mild hypothermia can ameliorate heart 
recovery when applied during ischemia (Stadelmann et al., 
2013) or during ischemia and reperfusion (Shao et al., 2007, 
2010; Hamamoto et al., 2009). 
The beneficial effects of hypothermia during ischemia 
(hypothermia Per-Con) on cardiomyocyte function, infarct size, 
no-reflow phenomenon, and cardiac remodeling have been 
demonstrated several times in different animal models (Hale et 
al., 2011; Dai et al., 2015). Energy preservation and intracellular 
signaling pathways, including PKC, Akt/PKB, ERK, PI3K, 
endothelial NOS and NO, have been reported to mediate 
cardioprotection afforded by mild hypothermia Per-Con (Yang 
et al., 2011; Tissier et al., 2012; Mochizuki et al., 2012; Shao et 
al., 2010). 
To the best of our knowledge a few studies demonstrated a 
positive role for temperature variation in PostCon procedures. 
In particular, Götber et al. (2011) reported an 18% reduction 
in infarct size when hypothermia started 40 minutes after the 
onset of ischemia and 5 minutes before the reperfusion (the 
total duration of ischemia was 45 min). In this study, a greater 
reduction in the size of the heart attack was obtained when 
hypothermia was started 25 minutes before the reperfusion 
and was maintained for 20 minutes during the reperfusion. 
However, the latter procedure does not exclude the possibility 
that the protection was due to hypothermic Per-Con rather than 
hypothermic PostCon. In a study in which mild hypothermia 
(30 °C) was instituted at the beginning of reperfusion for a brief 
period (10-min), improvements in post-ischemic developed left 
ventricular pressure, heart rate, contractility, cardiac output, 
and cardiac work, were observed compared with controls. 
These effects were accompanied by a reduction in necrosis 
(reduced LDH release), improved endothelial function (higher 
coronary flow), increased oxygen consumption, and a trend 
toward less cytochrome c release; thus suggesting better 
metabolic recovery (Farine et al., 2016). Moderate cooling 
also resulted in protection when applied during reperfusion 
for 60-min (Tolboom et al., 2016) or 180-min (Mochizuki 
et al., 2012). Recently, acceleration of autophagic flow and 
mitophagy has been reported as a central mechanism in the 
recovery of cardiomyocytes and mitigation of post-infarct 
remodeling when hypothermic conditions were induced 30-
min after the beginning of reperfusion (Marek-Iannucci et 
al., 2019). Therefore, it also seems that reperfusion injury, 
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in some circumstances, can be reduced with hypothermia. 
Moreover, the beneficial effect of ischemic PostCon could 
be additive with the beneficial effects of hypothermic Per-
Con. For instance, an ischemic PostCon protocol consisting 
of three 30-s episodes of global ischemia performed after 4-h 
of hypothermic rat heart storage (4-h of cold ischemia and 
cardioplegic protocol) resulted in improved post-ischemic LV 
function, reduced superoxide anion production, and suppressed 
reperfusion arrhythmias (Lauzier et al., 2007). In addition, 
hyperthermia-induced cardioprotection was potentiated by 
ischemic PostCon (Murozono et al., 2009). In this study 
hyperthermia (43 °C for 20 min) was applied 24-h before 
ischemia onset. Ischemic PostCon obtained with 5 cycles of 10-
sec reperfusion/10-sec ischemia potentiated the cardioprotective 
effects of hyperthermia likely via enhancement of reperfusion-
induced Akt phosphorylation. Nevertheless, the opening of the 
mitochondrial ATP-sensitive potassium (mitoKATP) channel, 
which is involved in hyperthermia-induced cardioprotection, 
is not necessary to potentiate protection induced by ischemic 
PostCon. However, these PostC studies need to be further 
confirmed in other models as a number of authors are convinced 
that thermic approaches cannot reduce reperfusion injury 
(Tissier et al., 2012).
6.2 Remote ischemic conditioning procedures and temperature
Remote ischemic conditioning (RIC) is the interesting 
phenomenon whereby brief, non-lethal episodes of ischemia 
and reperfusion applied in one organ, tissue, or vascular bed 
renders the whole body and each organ resistant to IRI (Candilio 
et al., 2013) (Fig 2). RIC can be attained in animals with 
brief episodes of ischemia/reperfusion in mesentery, kidney, 
or limbs. Besides remote ischemic PreCon, in which brief 
intermittent periods of ischemia (generally 3-4 cycles of 5 min 
ischemia) are applied before the onset of index myocardial 
ischemia, cardioprotection can also be attained with concurrent 
application of the remote ischemic stimulus during index 
coronary occlusion (remote ischemic Per-Con), or at the time 
of reperfusion (remote ischemic PostCon) (Przyklenk et al., 
2011; Vinten-Johansen and Shi, 2011; Heusch et al., 2015). 
Studies revealed no apparent difference in efficacy of ischemic 
remote PreCon, Per-Con, and remote PostCon (Basalay et 
al., 2012; Zhu et al., 2013; Penna et al., 2015). Limb RIC 
significantly reduced infarct size in humans and in animal 
in vivo models of myocardial IRI. However, the recent large 
multicenter 5401 ST-elevation myocardial infarction (STEMI) 
patients CONDI2/-ERIC-PPCI trial, failed to show any clinical 
benefit of limb RIC, with no differences with respect to 
control. Intriguingly, in a systematic review and meta-analysis 
a significant heterogeneity in effect size was described that 
could not be explained by any of the experimental variables 
analyzed by meta-regression (Bromage et al., 2017). From the 
analysis it emerged that studies lacked consistency in quality 
and study design. Moreover, to the best of our knowledge 
no studies considered the temperature of the ischemic limb 
among the variables to be controlled (limb temperature was 
also not mentioned in the above meta-analysis). Since in the 
ischemic limb temperature can decrease in a variable way, 
it is surprising that this important parameter is not strictly 
controlled during RIC maneuvers. There is, therefore, an urgent 
necessity for more well-performed and standardized in vivo 
studies with particular emphasis on detailed characterization 
of RIC protocols and investigating the potential impact of limb 
temperature. Standardized remote conditioning protocol(s) 
performed at controlled limb temperature may be used to 
increase the efficacy of this powerful approach. In a preliminary 
study we have evidence that controlling the temperature of the 
limbs (avoiding the cooling of the limbs during conditioning) 
can improve the effectiveness of RIC.
In a recent study it has been proposed that remote ischemic 
PostCon alone or associated with hypothermia may improve 
postresuscitation cardiac and neurological outcomes in pigs 
(Xu et al., 2016). Remote ischemic PostCon was induced in 
swine by 4 cycles of limb ischemia followed by reperfusion. 
Hypothermia was achieved by surface-cooling to establish 
a body temperature of 32-34 °C. In animals that underwent 
remote ischemic PostCon, a larger stroke volume and an 
improved cardiac ejection fraction, as well as better cerebral 
function 72-h after resuscitation, was observed. Also reduced 
levels of cardiac troponin I and NSE were detected in these 
animals when compared to the control. The combination of 
remote ischemic PostCon plus hypothermia resulted in greater 
recovery in cardiac and neurological function when compared 
with remote ischemic PostCon alone (Xu et al., 2016). 
Surprisingly, we cannot find other studies that combined RIC 
with hypo- or hyperthermia. The possibility that negative results 
were not published cannot be ruled out.
7. Studies in perspective
Temperature is an important variable affecting IRI that deserve 
to be strictly controlled and eventually modified to amplify 
the efficacy of cardioprotective strategies. Nevertheless, more 
in depth studies are necessary to understand the mechanisms 
of protection by thermic therapy alone and in association with 
other cardioprotective interventions. Several issues are still 
opened. For instance, no studies defined the role of the various 
cell death types in reducing injury following the application 
of thermic therapies in the attenuation of IRI, and whether 
modification of death pathways may be influenced in the 
presence of co-morbidities (e.g. age, obesity, diabetes, etc). 
Very few studies analyzed the role of miRNA, exosomes, or 
microvesicles. These are challenges that must be addressed and 
overcome for better exploitation of this powerful therapeutic 
strategy. Since the mechanism of protection by thermic therapy 
may differ from that of ischemic conditioning (for example, 
hypothermia during ischemia prevents cardiac stunning, 
whereas ischemic pre and postconditioning do not), it should be 
possible to add thermic therapy and conditioning procedures to 
produce ‘amplified protection’.
8. Conclusions 
Bes ides  the rmic  the rapy  to  be t t e r  s to re  hear t s  fo r 
transplantation, three distinct time windows are proposed for the 
use of thermic therapy to reduce IRI in the beating heart. The 
first window is before ischemia, which is temperature PreCon. 
This can be applied alone or in association with other strategies 
in programmed interventions. Cooling or heating during this 
window may serve to trigger and amplify cardioprotective 
signaling pathways. The majority of studies support the 
notion that cooling may blunt ischemic PreCon effectiveness, 
whereas moderate heating may potentiate it. The second 
window of opportunity is during ischemia, that is temperature 
Per-Con. In this window moderate/mild cooling seems to be 
the only thermic cardioprotective option, while deep cooling 
may require cardiac arrest. In the beating heart, moderate/
mild cooling during this window may target ROS production, 
calcium, and other ion management, as well as pH control. The 
third window is the PostCon during early reperfusion (during 
the first minutes of reperfusion) or during late reperfusion 
(hours after the beginning of reperfusion), which is termed 
temperature PostCon. Early thermic PostCon treatment may 
target mechanisms similar to those of PreCon or Per-Con, 
whereas late thermic PostCon may target mainly delayed 
pathways to cell death, and inflammatory and maladaptive 
processes. Theoretically, an extraordinary opportunity, scarcely 
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explored, is remote temperature conditioning, associated or not 
with RIC.
It must be recognized, however, that the control of 
temperature is complex in nature and this complexity may be 
responsible for the discordant results among various studies 
in terms of the time course and potency of cooling-induced 
cardioprotection, especially in humans. These difficulties 
must not dampen enthusiasm for studying this powerful 
cardioprotective strategy. Indeed, a better understanding 
of temperature-triggered myocardial resistance against IRI 
may have a large spectrum of clinical implications as well as 
insightful into the thermic biology.
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